Altman Advisors Inc. Takes Position in Gilead Sciences, Inc. $GILD

Key Points

• Altman Advisors initiated a new Gilead Sciences position in the second quarter, purchasing 21,931 shares valued at approximately $2.77 million. Institutional investors collectively own 83.67% of the company.
• Gilead reported quarterly revenue of $7.80 billion, up 10.6% year over year, and beat analysts’ adjusted EPS expectations despite posting a net loss. The company also declared a quarterly dividend of $0.82, yielding approximately 2.3% annually.
• Analyst sentiment remains generally positive, with a consensus “Moderate Buy” rating and a $158.04 target price, although some firms lowered targets. Company insiders sold 82,000 shares worth about $10.84 million over the past three months under pre-arranged trading plans.

Altman Advisors Inc. purchased a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 21,931 shares of the biopharmaceutical company's stock, valued at approximately $2,771,000.

Several other institutional investors and hedge funds have also modified their holdings of the business. Aviva PLC boosted its position in Gilead Sciences by 5.4% during the 4th quarter. Aviva PLC now owns 1,156,738 shares of the biopharmaceutical company's stock worth $141,978,000 after buying an additional 59,782 shares during the period. Life Cycle Investment Partners Ltd acquired a new position in Gilead Sciences in the 4th quarter valued at approximately $1,418,000. NBC Securities Inc. increased its position in Gilead Sciences by 150.3% in the 4th quarter. NBC Securities Inc. now owns 17,147 shares of the biopharmaceutical company's stock valued at $2,105,000 after acquiring an additional 10,296 shares during the period. Flputnam Investment Management Co. raised its stake in shares of Gilead Sciences by 66.5% during the fourth quarter. Flputnam Investment Management Co. now owns 105,740 shares of the biopharmaceutical company's stock valued at $12,978,000 after acquiring an additional 42,243 shares during the last quarter. Finally, Harvest Fund Management Co. Ltd lifted its holdings in shares of Gilead Sciences by 14.4% during the fourth quarter. Harvest Fund Management Co. Ltd now owns 106,526 shares of the biopharmaceutical company's stock worth $13,075,000 after purchasing an additional 13,385 shares during the period. 83.67% of the stock is currently owned by institutional investors.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the company's stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $138.36, for a total transaction of $415,080.00. Following the transaction, the chief financial officer directly owned 165,646 shares of the company's stock, valued at approximately $22,918,780.56. This represents a 1.78% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O'day sold 15,000 shares of the stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $130.31, for a total value of $1,954,650.00. Following the completion of the transaction, the chief executive officer owned 592,133 shares in the company, valued at approximately $77,160,851.23. The trade was a 2.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 82,000 shares of company stock valued at $10,837,860 in the last three months. Corporate insiders own 0.30% of the company's stock.

Gilead Sciences Price Performance

GILD stock opened at $143.44 on Friday. The firm has a market cap of $177.86 billion, a price-to-earnings ratio of -53.72 and a beta of 0.32. The company has a quick ratio of 1.09, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. Gilead Sciences, Inc. has a 12-month low of $108.46 and a 12-month high of $157.29. The company's fifty day simple moving average is $131.56 and its 200 day simple moving average is $136.52.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) EPS for the quarter, beating analysts' consensus estimates of ($7.25) by $0.50. The business had revenue of $7.80 billion for the quarter, compared to analysts' expectations of $7.40 billion. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The business's quarterly revenue was up 10.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.01 earnings per share. On average, analysts expect that Gilead Sciences, Inc. will post -0.51 earnings per share for the current year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th will be paid a $0.82 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $3.28 annualized dividend and a dividend yield of 2.3%. Gilead Sciences's dividend payout ratio (DPR) is currently -122.85%.

Analyst Upgrades and Downgrades

GILD has been the topic of several analyst reports. Daiwa Securities Group reduced their price objective on shares of Gilead Sciences from $161.00 to $150.00 and set an "outperform" rating on the stock in a research note on Tuesday, May 19th. Wall Street Zen raised Gilead Sciences from a "hold" rating to a "buy" rating in a research report on Saturday, August 15th. Needham & Company LLC reaffirmed a "buy" rating and set a $170.00 target price on shares of Gilead Sciences in a report on Wednesday, August 5th. Truist Financial reduced their price target on Gilead Sciences from $157.00 to $156.00 and set a "buy" rating on the stock in a research report on Tuesday, July 7th. Finally, Leerink Partners cut Gilead Sciences from an "outperform" rating to a "market perform" rating and decreased their price target for the company from $146.00 to $127.00 in a research note on Tuesday, July 21st. Twenty-four analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $158.04.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead’s collaboration with Nucleai highlights a potential strategic shift toward data-driven oncology. Nucleai’s spatial-biology and artificial-intelligence capabilities could help Gilead identify biomarkers, improve patient selection and support its cancer-drug pipeline, although the financial impact remains uncertain. Does Gilead Pairing With Nucleai Reveal a Deeper Shift in Its Oncology Strategy?
• Positive Sentiment: BMO Capital reaffirmed its Buy rating, reinforcing the view that Gilead’s HIV franchise, oncology investments and pipeline can support further gains. BMO Capital Reaffirms Buy Rating on Gilead Sciences
• Positive Sentiment: Zacks Research raised its FY2026 EPS forecast from a loss of $1.05 to a loss of $0.65 and increased its FY2027 estimate from $9.11 to $9.30. Several quarterly estimates for late 2026 and 2027 were also raised, suggesting improving expectations for future profitability.
• Neutral Sentiment: The recent rally extended to seven consecutive sessions, indicating strong momentum, but the subsequent consolidation may reflect profit-taking as the stock trades near its 52-week high. Gilead Rises for the Seventh Straight Session
• Neutral Sentiment: Gilead declared a quarterly dividend of $0.82, equivalent to $3.28 annually and a yield of roughly 2.3%. The payout supports income-oriented investors, though the reported negative payout ratio reflects currently distorted earnings.
• Negative Sentiment: Zacks lowered its FY2028 EPS forecast from $10.00 to $9.58 and cut estimates for Q1 and Q2 2028. Although several nearer-term estimates increased, the mixed revisions signal uncertainty around the longer-term earnings trajectory.
• Negative Sentiment: CFO Andrew Dickinson sold 3,000 shares for approximately $415,000. The transaction occurred under a pre-arranged Rule 10b5-1 plan and left him with substantial holdings, making it a limited bearish signal, but insider selling can weigh modestly on sentiment. Gilead Sciences CFO Sells 3,000 Shares

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source